Facebook
Twitter
LinkedIn
Forward
Paving the Way to Novel Therapies in CLL: Real World Patient Cases for the Oncology Pharmacist
Attendees of this initiative will gain exposure to emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors. There will also be discussion on strategies to optimize patient satisfaction and communication by addressing clinical challenges, promotion of patient adherence, proper management of adverse events, and the encouragement of open communication between provider and patient. This educational initiative will be interactive, with attendees following the patient journey through real-world cases and polling questions incorporated throughout.
Supported through an independent educational grant from AstraZeneca.
Target Audience
This activity is designed to meet the educational needs of hospital and health-system pharmacists, pharmacy directors, and pharmacy residents.
Learning Objectives
At the conclusion of this application-based activity, participants will be able to:
- Discuss the molecular pathophysiology associated with the development of CLL, the role of the B-cell receptor (BCR) pathway, and the rationale for therapeutically targeting this pathway.
- Appraise recent clinical safety and efficacy data in novel CLL therapies for use in both monotherapy and combination, focusing on differentiating factors seen among the various agents.
- Assess the latest clinical CLL guideline recommendations for selection and sequencing of therapy, individualized to the patient, including mutation status, performance status, comorbidities, and patient preferences.
- Using a case-based approach, explore the various clinical challenges pharmacists face with the use of CLL novel therapies in practice, including preventing and managing toxicities, promoting patient adherence, and fostering a team-based environment to improve patient care. and appropriately manage adverse events, and answer challenging clinical issues pharmacists may encounter in their practice.
Additional Information
| Attachment | Size |
|---|---|
 7.9.21 Handout.pdf | 2.27 MB |
5 min Welcome and Introductions/Pre-test
15 min Targeting the BCR Pathway in Chronic Lymphocytic Leukemia: A Novel Therapy Revolution
30 min Navigating the Patient Journey: A Case-based Discussion on Chronic Lymphocytic Leukemia Management
10 min Q&A/Post-test
Rebecca J. Nelson, PharmD, BCOP
Clinical Pharmacy Coordinator, Malignant Hematology
Moffitt Cancer Center
Tampa, FL
Dr. Nelson is the Clinical Pharmacy Coordinator for the Malignant Hematology division at Moffitt Cancer Center and Research Institute.
She currently supervises a team of hematology pharmacists and practices across the inpatient and outpatient setting. She has experience in multiple practice areas, leads numerous process improvement projects, and collaborates with hematologists on research projects within her institution. She received her Doctor of Pharmacy from Lake Erie College of Osteopathic Medicine School of Pharmacy and her Bachelors of Science in Molecular Biology and Microbiology from the University of Central Florida. She completed two years of postgraduate residency training at Moffitt Cancer Center and went on to receive her Board Certification in Oncology Pharmacy. She is a member of multiple professional organizations and speaks nationally on drug and disease topics.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
PLANNERS
Vanessa Carranza, PharmD, has no relevant financial relationships to disclose in relation to the content of this activity.
PRESENTERS
Emily K. Dotson, PharmD, BCOP–has disclosed that she is a consultant for AstraZeneca.
Rebecca J. Nelson, PharmD, BCOP–has disclosed that she is a consultant for AbbVie, BTG, and Stemline.
Jeannie Patrick, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
PEER REVIEWER
Alison Duffy, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-21-010-L01-P).
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
Available Credit
- 1.00 ACPE Pharmacy
- 1.00 Participation